Condensed Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:
Research and development programs	$ 6,917	$ 6,260	$ 11,960	$ 8,940
Product revenues	9,022	4,915	16,370	8,915
Total revenues	15,939	11,175	28,330	17,855
Costs and operating expenses:
Cost of product revenues	4,470	1,496	7,860	2,950
Research and development	22,064	14,915	42,899	28,635
Sales, general and administrative	21,637	15,436	42,244	30,302
Total costs and operating expenses	48,171	31,847	93,003	61,887
Loss from operations	(32,232)	(20,672)	(64,673)	(44,032)
Other income (expense):
Interest and other income, net	393	371	628	719
Interest expense	(5,055)	(1,810)	(6,402)	(3,681)
Loss from equity method investments	(4,278)	(2,222)	(8,112)	(3,181)
(Loss) gain from change in fair value of warrant liability	0	(679)	688	(625)
(Loss) gain from change in fair value of derivative liabilities	(1,745)	(813)	273	(1,550)
Total other income (expense)	(10,685)	(5,153)	(12,925)	(8,318)
Net loss	$ (42,917)	$ (25,825)	$ (77,598)	$ (52,350)
Net loss per share, basic and diluted	$ (0.56)	$ (0.42)	$ (1.07)	$ (0.85)
Weighted average number of common shares used in loss per share computation, basic and diluted	75,963,290	61,957,939	72,606,733	61,751,371